THE WORLD Health Organization or WHO has updated its living guideline on COVID-19 therapeutics to include convalescent plasma.
For
non-severe COVID-19 patients, WHO recommends against its use, while it should
only be used within clinical trials for severe and critical COVID-19 patients.
Convalescent
plasma is a transfusion of blood plasma from someone who has recovered from
COVID-19.
Current
evidence shows that convalescent plasma does not improve survival or reduce the
need for mechanical ventilation, while it has significant costs.
An
independent panel of experts, the guidelines development group, looked at
pooled data from 16 randomized controlled trials, including 16,236 patients
with non-severe, severe, and critical COVID-19 infection.
While
the evidence that convalescent plasma has no benefit in non-severe patients was
certain, it was less so in the case of severe and critically ill patients. So,
randomized clinical trials for these subgroups should continue, according to
WHO. (Zamboanga Post)
No comments:
Post a Comment